Muscular dystrophy is a group of inherited diseases that cause progressive muscle weakness and loss of muscle mass. More than 30 types exist, each caused by mutations in genes responsible for producing proteins that keep muscle fibers intact. The most well-known of these proteins is dystrophin, which acts like a shock absorber for muscle cells. When dystrophin is absent, deficient, or structurally abnormal, muscle cell membranes become unstable during normal use, leading to damage, inflammation, and eventually the replacement of muscle tissue with fat and scar tissue.
How Genetic Mutations Cause Muscle Loss
Every time a muscle contracts, its cell membranes endure mechanical stress. Dystrophin and its associated proteins form a complex that anchors the internal structure of the muscle cell to the membrane and the surrounding tissue, distributing that stress evenly. Without this stabilizing framework, even routine movements cause tiny tears in the membrane. The body repairs this damage at first, but over months and years the cycle of damage and repair exhausts the muscle’s ability to regenerate. Muscle fibers die off and are gradually replaced by tissue that can’t contract.
The specific gene mutation determines which type of muscular dystrophy develops. In the two most common childhood forms, Duchenne and Becker, the mutations occur in the same gene on the X chromosome. The critical difference: mutations that completely prevent the production of functional dystrophin cause the severe Duchenne form, while mutations that allow a shortened but partially working version of dystrophin to be made result in the milder Becker form.
The Major Types
Duchenne Muscular Dystrophy
Duchenne is the most common and severe childhood form, affecting roughly 1 in 5,000 boys. Symptoms typically appear between ages 2 and 6, often showing up as clumsiness, difficulty climbing stairs, toe-walking, and trouble getting up from the floor. A hallmark sign is when a child pushes off their own thighs with their hands to stand up, known as Gowers’ sign. Because the gene sits on the X chromosome, Duchenne occurs almost exclusively in boys. Girls can carry the mutation and very rarely develop milder symptoms.
The disease progresses through recognizable stages. Between ages 6 and 9, symptoms worsen but children generally maintain the ability to walk. Most boys lose the ability to walk independently between ages 10 and 14, transitioning to a power wheelchair around 12 to 15. By adolescence, breathing muscles begin to weaken, causing shallow breathing during sleep and a weaker cough. Heart muscle is also affected: cardiomyopathy and irregular heart rhythms appear in the teenage years, and heart failure develops in more than 80% of those over 18.
Becker Muscular Dystrophy
Becker follows a similar pattern to Duchenne but on a much slower timeline. Symptoms usually emerge in the teen years or early adulthood, and because the body still produces some functional dystrophin, muscle strength declines more gradually. Many people with Becker remain ambulatory well into adulthood, and survival commonly extends into middle age. Heart involvement can still be significant, though, and sometimes the cardiac symptoms are more prominent than the skeletal muscle weakness.
Myotonic Dystrophy
Myotonic dystrophy is the most common form diagnosed in adults, typically appearing between ages 20 and 40. Its signature feature is myotonia, a prolonged stiffness after muscle contraction. You might grip a doorknob and find it difficult to release your hand quickly, or notice that your muscles are slow to relax after any sustained effort. Weakness tends to start in the face, hands, feet, and neck, then progresses slowly over decades.
What sets myotonic dystrophy apart is that it affects far more than muscles. Up to 90% of people with myotonic dystrophy type 1 develop heart conduction problems, meaning the electrical signals that coordinate heartbeats become disrupted. This is a significant cause of early death and sometimes leads to sudden cardiac events. Nearly all affected individuals develop distinctive cataracts, usually causing visual symptoms in their 30s or 40s. The disease can also disrupt hormone regulation, increasing the risk of diabetes, thyroid dysfunction, and infertility. Because of this whole-body involvement, people with myotonic dystrophy typically need regular heart monitoring, eye exams, and blood sugar checks.
Facioscapulohumeral Dystrophy (FSHD)
FSHD first affects the muscles of the face, shoulders, and upper arms, often becoming noticeable in childhood or early adulthood. Progression is generally slow, though some people experience periods of rapid deterioration. Many individuals with FSHD live a normal or near-normal lifespan. The condition can be asymmetric, affecting one side of the body more than the other, which distinguishes it from most other forms.
How Muscular Dystrophy Is Diagnosed
A blood test measuring creatine kinase (CK) is typically the first step. CK is an enzyme that leaks out of damaged muscle cells into the bloodstream, so elevated levels signal that muscle tissue is breaking down. In Duchenne, CK levels can rise to 10 times the upper limit of normal within the first three years of life, sometimes even before obvious symptoms appear. The European Academy of Neurology recommends further evaluation when CK levels are at least 1.5 times higher than the normal threshold.
Genetic testing confirms the diagnosis and identifies the exact mutation, which matters because some newer treatments target specific types of genetic defects. Most definitive diagnoses happen at specialized medical centers where genetic testing and, when needed, muscle biopsies are available. Early diagnosis is valuable because it opens the door to timely treatment, genetic counseling for the family, and screening of other relatives who may carry the mutation.
Treatment and Managing Symptoms
No cure exists for any form of muscular dystrophy, but treatments can meaningfully slow progression and improve quality of life. Corticosteroids remain the backbone of treatment for Duchenne. These medications improve muscle strength and lung function, and can delay the loss of walking ability by roughly 1.4 to 2.5 years. The trade-offs are real, though: long-term use commonly causes weight gain, shorter stature, behavioral changes, bone fractures, and changes in facial appearance. One formulation carries a higher risk of cataracts than the other, though most of these cataracts don’t significantly impair vision.
In 2023, the FDA approved a gene therapy called Elevidys for Duchenne, available to children aged 4 and older who can still walk and have a confirmed genetic mutation. This treatment uses a harmless virus to deliver a shortened version of the dystrophin gene directly into muscle cells, giving them the ability to produce a functional form of the protein they’re missing. It’s administered as a single intravenous infusion.
Beyond medication, physical therapy and stretching help maintain flexibility and slow the development of joint contractures. As the disease progresses, assistive devices like braces, walkers, and eventually power wheelchairs help maintain independence. Occupational therapy focuses on adapting daily tasks to remaining abilities.
Cardiac and Respiratory Care
For most people with Duchenne, the heart and lungs become the primary medical concern as they enter their teens and twenties. As breathing muscles weaken, the first signs are often fragmented sleep, morning headaches, daytime fatigue, and a weak cough that makes clearing respiratory infections difficult. Breathing support through a mask (noninvasive ventilation) is typically introduced around age 18 on average, initially just at night. Clinical guidelines recommend starting this support when a person develops symptoms of nighttime breathing problems along with evidence of carbon dioxide buildup, or when lung capacity drops below 50% of predicted values.
Heart medications that reduce strain on the heart muscle are started when monitoring detects early signs of weakening. An Australian study tracking 50 years of outcomes found that the combination of corticosteroids, heart medications, and breathing support increased median survival from about 19 years in untreated individuals to over 26 years. For those born in the 1990s, median survival reached 24 years, a notable increase from 18.2 years for those born before 1970. The probability of surviving past age 20 has risen steadily with each decade as care has improved.
Living With Muscular Dystrophy
The day-to-day experience varies enormously by type. Someone with FSHD may live decades with manageable shoulder weakness, while a teenager with Duchenne may be navigating the transition to full-time wheelchair use and nighttime breathing support simultaneously. For adolescents and young adults with Duchenne, the loss of walking is a pivotal moment, one that coincides with the already complex transition from childhood to adulthood. Beyond the physical challenges, this period brings shifts in independence, social life, and self-image that families and care teams need to address alongside the medical management.
Multidisciplinary care, involving neurologists, cardiologists, pulmonologists, physical therapists, and mental health professionals, has become standard at specialized neuromuscular centers. This coordinated approach is a major reason survival and quality of life have improved so significantly over the past several decades, even before gene therapy entered the picture.